| abstract |
Provided herein is a combination of oligoclonal anti-epidermal growth factor receptor (anti-EGFR) antibodies (e.g., MM‑151, comprising a first monoclonal antibody (P1X), a second monoclonal antibody (P2X) and a third monoclonal antibody (P2X) and a third monoclonal antibody A method of cloning an antibody (P3X), wherein P1X, P2X and P3X are in a 2:2:1 molar ratio) for treating epidermal growth factor receptor (EGFR) extracellular domain (ECD) mutant cancer in said human patient. In one embodiment, said cancer comprises at least one mutation in said extracellular domain of EGFR selected from the group consisting of EGFR R451C, S464L, K467T, G465R, G465E, I491M and S492R. |